Reasons patients decline or are unable to receive home-based treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study wants to learn why some patients choose not to receive treatment at home or are not able to. If you have multiple myeloma or acute leukemia and are on certain treatments, your input could help improve home-based care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with multiple myeloma or acute leukemia.
- You are currently receiving treatment with daratumumab (for myeloma) or cytarabine (for leukemia).
- You do not have dementia, a psychotic disorder, or other cognitive impairment that would limit participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
This study looks at how the immune system changes in patients with multiple myeloma who have had treatment that targets a protein called BCMA. It may help doctors understand why some treatments stop working and how to improve future care.
This study looks at whether people with multiple myeloma can safely give themselves daratumumab injections at home, instead of going to the hospital each time. You'll get the same medicine, but learn to manage it yourself with support, and share your experience through questionnaires and an interview.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study collects information and samples from people with multiple myeloma or related blood disorders to understand why the disease affects people differently. Researchers will use this information to develop better, personalized treatment approaches.
Hear when a new Multiple Myeloma Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.